Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Payables (2016 - 2025)

Lipocine (LPCN) has disclosed Payables for 13 consecutive years, with $861452.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables rose 201.9% year-over-year to $861452.0, compared with a TTM value of $861452.0 through Sep 2025, up 201.9%, and an annual FY2024 reading of $271696.0, down 80.54% over the prior year.
  • Payables was $861452.0 for Q3 2025 at Lipocine, up from $442994.0 in the prior quarter.
  • Across five years, Payables topped out at $1.4 million in Q4 2023 and bottomed at $271696.0 in Q4 2024.
  • Average Payables over 5 years is $691975.2, with a median of $630456.0 recorded in 2022.
  • The sharpest move saw Payables crashed 80.54% in 2024, then soared 201.9% in 2025.
  • Year by year, Payables stood at $1.3 million in 2021, then tumbled by 53.43% to $600388.0 in 2022, then skyrocketed by 132.51% to $1.4 million in 2023, then plummeted by 80.54% to $271696.0 in 2024, then soared by 217.06% to $861452.0 in 2025.
  • Business Quant data shows Payables for LPCN at $861452.0 in Q3 2025, $442994.0 in Q2 2025, and $360239.0 in Q1 2025.